Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting

Yu Ning Wong*, Brian L. Egleston, Kush Sachdeva, Naa Eghan, Melanie Pirollo, Tammy Kay Stump, John Robert Beck, Katrina Armstrong, Jerome Sanford Schwartz, Neal J. Meropol

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

BACKGROUND: When making treatment decisions, cancer patients must make trade-offs among efficacy, toxicity, and cost. However, little is known about what patient characteristics may influence these trade-offs. METHODS: A total of 400 cancer patients reviewed 2 of 3 stylized curative and noncurative scenarios that asked them to choose between 2 treatments of varying levels of efficacy, toxicity, and cost. Each scenario included 9 choice sets. Demographics, cost concerns, numeracy, and optimism were assessed. Within each scenario, we used latent class methods to distinguish groups with discrete preferences. We then used regressions with group membership probabilities as covariates to identify associations. RESULTS: The median age of the patients was 61 years (range, 27-90 y). Of the total number of patients included, 25% were enrolled at a community hospital, and 99% were insured. Three latent classes were identified that demonstrated (1) preference for survival, (2) aversion to high cost, and (3) aversion to toxicity. Across all scenarios, patients with higher income were more likely to be in the class that favored survival. Lower income patients were more likely to be in the class that was averse to high cost (P<0.05). Similar associations were found between education, employment status, numeracy, cost concerns, and latent class. CONCLUSIONS: Even in these stylized scenarios, socioeconomic status predicted the treatment choice. Higher income patients may be more likely to focus on survival, whereas those of lower socioeconomic status may be more likely to avoid expensive treatment, regardless of survival or toxicity. This raises the possibility that insurance plans with greater cost-sharing may have the unintended consequence of increasing disparities in cancer care.

Original languageEnglish (US)
Pages (from-to)838-845
Number of pages8
JournalMedical care
Volume51
Issue number9
DOIs
StatePublished - Sep 2013

Keywords

  • Cancer
  • Decision-making
  • Health economics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting'. Together they form a unique fingerprint.

Cite this